Bococizumab + Placebo
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Hyperlipidemia or Mixed Dyslipidemia
Conditions
Primary Hyperlipidemia or Mixed Dyslipidemia
Trial Timeline
Oct 31, 2016 → May 3, 2019
NCT ID
NCT02947334About Bococizumab + Placebo
Bococizumab + Placebo is a phase 3 stage product being developed by Pfizer for Primary Hyperlipidemia or Mixed Dyslipidemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02947334. Target conditions include Primary Hyperlipidemia or Mixed Dyslipidemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02947334 | Phase 3 | Withdrawn |
| NCT02524106 | Phase 3 | Terminated |
Competing Products
20 competing products in Primary Hyperlipidemia or Mixed Dyslipidemia